GlassScriptPhysician profile
Carolyn E Graham
NPI 1548612682
$4,204.10
in general payments reported to CMS, 2019-2025
33 companies · $991 in 2025
The $991 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $581 · 2023: $1,282 · 2024: $1,351 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.02 | 2022-2025 | |
| Lilly USA, LLC | $530.99 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $430.38 | 2022-2025 | |
| Astellas Pharma US INC | $286.04 | 2023-2025 | Veozah, Myrbetriq |
| Radius Health, INC. | $247.72 | 2022-2025 | Tymlos |
| Novo Nordisk INC | $231.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $195.78 | 2022-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $181.11 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.30 | 2022-2025 | Ofev, Jardiance |
| Xeris Pharmaceuticals, INC. | $167.55 | 2022-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $100.96 | 2024-2025 | Voquezna |
| Medtronic, INC. | $75.21 | 2022-2024 | Minimed 770g |
| Biohaven Pharmaceutical Holding Company LTD. | $68.03 | 2022 | |
| Corcept Therapeutics | $68.02 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.12 | 2022-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $60.10 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $56.59 | 2023-2025 | Gattex, Hyqvia |
| Seqirus USA INC | $55.34 | 2023-2024 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Exact Sciences Corporation | $54.06 | 2023-2024 | Cologuard Collection Kit |
| Optinose US, INC. | $53.94 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $51.85 | 2024-2025 | Airsupra |
| Glaxosmithkline, LLC. | $46.56 | 2024-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $46.36 | 2022-2023 | |
| Dynavax Technologies Corporation | $43.23 | 2023 | Heplisav-B |
| Dexcom, INC. | $27.15 | 2023 | Dexcom G6 Transmitter |
| Vbi Vaccine (Delaware) INC. | $26.22 | 2023 | Prehevbrio |
| Madrigal Pharmaceuticals | $22.64 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $21.89 | 2023 | Spravato |
| Axsome Therapeutics, INC. | $19.00 | 2024 | Auvelity |
| Hologic Sales and Service, LLC | $18.99 | 2024 | Aptima |
| Esperion Therapeutics, INC. | $17.29 | 2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $14.27 | 2024 | Eliquis |
| Amneal Pharmaceuticals LLC | $13.95 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.